This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Scientific Reports Open Access 27 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.
Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M . Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009; 417: 651–666.
Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665–683.
Wang WA, Groenendyk J, Michalak M . Calreticulin signaling in health and disease. Int J Biochem Cell Biol 2012; 44: 842–846.
Burns K, Duggan B, Atkinson EA, Famulski KS, Nemer M, Bleackley RC et al. Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 1994; 367: 476–480.
Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013; 123: 1552–1555.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013; 123: 1544–1551.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 2014; e-pub ahead of print 9 January 2014; doi:10.1038/leu.2014.3.
Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013; 27: 2072–2075.
Thol F, Kolking B, Hollink IH, Damm F, van den Heuvel-Eibrink MM, Michel Zwaan C et al. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia 2012; 27: 750–754.
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia, 2014; e-pub ahead of print 7 February 2014; doi:10.1038/leu.2014.66.
Tefferi A, Thiele J, Vannucchi AM, Barbui T . An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia, 2014; e-pub ahead of print 20 January 2014; doi:10.1038/leu.2014.35.
Hou HA, Kuo YY, Chou WC, Chen PH, Tien HF . Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome. Leukemia, 2014; e-pub ahead of print 17 February 2014; doi:10.1038/leu.2014.71.
Broseus J, Lippert E, Klampfl T, Jeromin S, Zipperer E, Florensa L et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014; 28: 1374–1376.
Patnaik MM, Belachew A, Finke C, Lasho TL, Hanson CA, Tefferi A . CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia 2014; 28: 1370–1371.
Acknowledgements
We are indebted to all patients and contributing doctors. We thank Elke Dammann and Wolfgang Kühnau for support in sample and data acquisition. This study was supported by grants 109003, 110284, 110287 and 110292 from Deutsche Krebshilfe; grants DJCLS H09/1f, R 10/22 and SP 12/02 from the Deutsche-José-Carreras Leukämie-Stiftung e.V; the German Federal Ministry of Education and Research grant 01EO0802 (IFB-Tx); DFG grant HE 5240/5-1; and grants from Hamburger Krebsgesellschaft, Erich und Gertrud Roggenbuck Stiftung and Dieter-Schlag Stiftung.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Heuser, M., Panagiota, V., Koenecke, C. et al. Low frequency of calreticulin mutations in MDS patients. Leukemia 28, 1933–1934 (2014). https://doi.org/10.1038/leu.2014.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.165
This article is cited by
-
CALR loss-of-heterozygosity as a potential driver for extramedullary AML
Annals of Hematology (2022)
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Scientific Reports (2019)
-
Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis
Annals of Hematology (2017)
-
Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia
Annals of Hematology (2015)